



NEWS RELEASE

# Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

2024-09-26

THE WOODLANDS, TX, Sept. 26, 2024 (GLOBE NEWSWIRE) -- **Autonomix Medical, Inc.** (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the **Company's website**. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, addressed Pain Awareness Month and what the Company is doing to address the significant unmet need in pancreatic cancer pain.

The CEO Corner segment is now available **here**.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United

States.

For more information, visit **autonomix.com** and connect with the Company on **X, LinkedIn, Instagram** and **Facebook**.

#### Forward Looking Statements

Some of the statements in the CEO Corner video are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in the CEO Corner video include, without limitation, the potential of the technology to treat pain associated with pancreatic cancer, to successfully enroll patients within the specific timeframe, and to complete its clinical study in pancreatic cancer pain. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

#### Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908.824.0775

**autonomix@jtcir.com**

Source: Autonomix Medical, Inc.